TCP
BMRN icon

Tourbillon Capital Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Tourbillon Capital Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-200,000
Closed -$21.1M – 78
2015
Q3 		$21.1M Buy
+200,000
New +$26.7M 0.55% 48

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tourbillon Capital Partners's BMRN Position: Q4 2018 in Review

Tourbillon Capital Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2018, closing a stake of 147,193 shares — an estimated $14.3M sold.

Tourbillon Capital Partners first reported a position in BMRN in Q3 2014 and held it in 5 quarters. The position peaked at $37.5M in Q4 2014. 473 funds tracked by Wall St. Rank hold BMRN as of Q4 2018.

  • Tourbillon Capital Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Tourbillon Capital Partners sold 147,193 BioMarin Pharmaceuticals shares in Q4 2018, an estimated $14.3M.
  • Tourbillon Capital Partners first reported a position in BioMarin Pharmaceuticals in Q3 2014 and held it in 5 quarters.
  • Tourbillon Capital Partners's BioMarin Pharmaceuticals position peaked at $37.5M in Q4 2014.
  • 473 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2018.

Based on Tourbillon Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.